Corresponding Author: Thomas R. Kosten, MD, Department of Psychiatry, Baylor College of Medicine, 1401 Calumet St, Unit 506, Houston, TX 77004 (firstname.lastname@example.org).
Published Online: December 30, 2020. doi:10.1001/jamapsychiatry.2020.4148
Conflict of Interest Disclosures: Dr Kosten reported consulting fees from Alkermes, BioXcel, Indivior, Opiant, and US World Meds. He also reports grant support from the National Institutes of Health (National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases), including for a fentanyl vaccine, and the Department of Defense. Dr Petrakis reported consulting fees from Alkermes outside the submitted work; in addition, Dr Petrakis had a patent related to ketamine and naltrexone pending.
Meeting Presentations: Portions of this Viewpoint were previously presented as CC Grand Rounds: “Contemporary Clinical Medicine, Great Teachers: Treating the Other Epidemic, Anti-Opioid Vaccines,” for the National Institutes of Health; September 9, 2020; virtually presented to an audience in Bethesda, Maryland.
et al. High Plasma Buprenorphine Concentrations Decrease Respiratory Effects of Intravenous Fentanyl. American Society for Addiction Medicine; 2019.
MD , Baruffaldi
F , Peterson
et al. A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats. J Pharmacol Exp Ther
. 2019;368(2):282-291. doi:10.1124/jpet.118.253674
QQ , Kaelber
DC , Xu
R , Volkow
ND . COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry
. 2020;1-10. doi:10.1038/s41380-020-00880-7PubMedGoogle Scholar